Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study - PubMed (original) (raw)
. 1996 Jun;38(6):1096-103; discussion 1103-4.
H B Levy, S Ondra, M Kende, B Scherokman, D Brown, H Mena, N Martin, K Schwab, D Donovan, D Dougherty, M Pulliam, M Ippolito, M Graves, H Brown, A Ommaya
Affiliations
- PMID: 8727138
Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study
A M Salazar et al. Neurosurgery. 1996 Jun.
Abstract
Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC) (10-50 mcg/kg, administered intramuscularly one to three times weekly) was given for < or = 56 months to 38 patients with malignant gliomas. There was minimal or no toxicity. Twenty of 30 patients (66%) receiving at least twice weekly poly-ICLC showed regression or stabilization of gadolinium-enhancing tumor, as revealed by magnetic resonance imaging (median = 65% volume decrease). All but one patient with anaplastic astrocytomas who received continuous poly-ICLC remain alive, with a median progression-free survival of 54 months from diagnosis. Median Kaplan-Meier survival is 19 months for patients with glioblastomas who receive at least twice weekly poly-ICLC treatments. Tumor response was associated with 2',5' -oligoadenylate synthetase activation (P = 0.03) but not with serum interferon. We hypothesize clinical activation by poly-ICLC of a basic host tumor suppressor system. Prolonged, quality survival with tumor stabilization or regression confirmed by magnetic resonance imaging for most patients with anaplastic astrocytomas and glioblastomas suggests that more extensive laboratory and controlled clinical studies are warranted. The concept of long-term, broad spectrum stimulation of host defenses with nontoxic, inexpensive double-stranded ribonucleic acids, such as low-dose poly-ICLC, may be applicable to the treatment of other malignancies.
Similar articles
- A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. Rosenfeld MR, et al. Neuro Oncol. 2010 Oct;12(10):1071-7. doi: 10.1093/neuonc/noq071. Epub 2010 Jul 8. Neuro Oncol. 2010. PMID: 20615924 Free PMC article. Clinical Trial. - Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
Migliorini D, Dutoit V, Allard M, Grandjean Hallez N, Marinari E, Widmer V, Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N, Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D, Vargas MI, Walker PR, Patrikidou A, Dietrich PY. Migliorini D, et al. Neuro Oncol. 2019 Jul 11;21(7):923-933. doi: 10.1093/neuonc/noz040. Neuro Oncol. 2019. PMID: 30753611 Free PMC article. Clinical Trial. - A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy.
De Waele J, Verhezen T, van der Heijden S, Berneman ZN, Peeters M, Lardon F, Wouters A, Smits ELJM. De Waele J, et al. J Exp Clin Cancer Res. 2021 Jun 25;40(1):213. doi: 10.1186/s13046-021-02017-2. J Exp Clin Cancer Res. 2021. PMID: 34172082 Free PMC article. Review. - High-grade astrocytomas.
Wen PY, Fine HA, Black PM, Shrieve DC, Alexander E 3rd, Loeffler JS. Wen PY, et al. Neurol Clin. 1995 Nov;13(4):875-900. Neurol Clin. 1995. PMID: 8584002 Review.
Cited by
- Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H. Zhu X, et al. J Transl Med. 2007 Feb 12;5:10. doi: 10.1186/1479-5876-5-10. J Transl Med. 2007. PMID: 17295916 Free PMC article. - Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors.
Wu CY, Yang HY, Monie A, Ma B, Tsai HH, Wu TC, Hung CF. Wu CY, et al. Cancer Immunol Immunother. 2011 Aug;60(8):1085-96. doi: 10.1007/s00262-011-1013-7. Epub 2011 Apr 28. Cancer Immunol Immunother. 2011. PMID: 21526359 Free PMC article. - A Potent Micron Neoantigen Tumor Vaccine GP-Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models.
Jing Z, Wang S, Xu K, Tang Q, Li W, Zheng W, Shi H, Su K, Liu Y, Hong Z. Jing Z, et al. Adv Sci (Weinh). 2022 Aug;9(24):e2201496. doi: 10.1002/advs.202201496. Epub 2022 Jun 16. Adv Sci (Weinh). 2022. PMID: 35712770 Free PMC article. - Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.
Garzon-Muvdi T, Theodros D, Luksik AS, Maxwell R, Kim E, Jackson CM, Belcaid Z, Ganguly S, Tyler B, Brem H, Pardoll DM, Lim M. Garzon-Muvdi T, et al. Oncotarget. 2018 Apr 17;9(29):20681-20697. doi: 10.18632/oncotarget.25061. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755681 Free PMC article. - Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.
Elion DL, Cook RS. Elion DL, et al. Oncotarget. 2018 Jun 22;9(48):29007-29017. doi: 10.18632/oncotarget.25626. eCollection 2018 Jun 22. Oncotarget. 2018. PMID: 29989043 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical